title: Survival and cardiac event rates in the first year after emergency coronary angioplasty for acute myocardial infarction.
abstract: One year survival and event-free survival rates were analyzed in 342 patients with acute myocardial infarction who were consecutively enrolled in a treatment protocol of early intravenous thrombolytic therapy followed by emergency coronary angioplasty. Ninety-four percent of the patients achieved successful reperfusion, including 4% with failed angioplasty whose perfusion was maintained by means of a reperfusion catheter before emergency bypass surgery. The procedural mortality rate was 1.2% and the total in-hospital mortality rate was 11%. Ninety-two percent of surviving nonsurgical patients who underwent repeat cardiac catheterization were discharged from the hospital with an open infarct-related artery. The related cumulative 1 year survival rate for all patients managed with this treatment strategy was 87%, and the cardiac event-free survival rate was 84%. The 1 year survival for hospital survivors was 98% and the infarct-free survival rate was 94%. Multivariable analysis identified the following factors as independent predictors of subsequent cardiovascular death: cardiogenic shock, greater age, lower ejection fraction, female gender and a closed infarct-related vessel on the initial coronary angiogram. Among patients with cardiogenic shock, despite a 42% in-hospital mortality rate, only 4% died during the first year after hospital discharge. Similarly, the in-hospital and 1 year postdischarge mortality rates were 19 and 4%, respectively, for patients with an initial ejection fraction less than 40, and 25 and 3%, respectively, for patients greater than 65 years. An aggressive treatment strategy including early thrombolytic therapy, emergency cardiac catheterization, coronary angioplasty and, when necessary, bypass surgery resulted in a high rate of infarct vessel patency.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Interventional Cardiac Catheterization Program, Duke University Medical Center, Durham, North Carolina 27710.
authors.forename: R S
authors.initials: RS
authors.lastname: Stack
authors.forename: R M
authors.initials: RM
authors.lastname: Califf
authors.forename: T
authors.initials: T
authors.lastname: Hinohara
authors.forename: H R
authors.initials: HR
authors.lastname: Phillips
authors.forename: D B
authors.initials: DB
authors.lastname: Pryor
authors.forename: C A
authors.initials: CA
authors.lastname: Simonton
authors.forename: E B
authors.initials: EB
authors.lastname: Carlson
authors.forename: K G
authors.initials: KG
authors.lastname: Morris
authors.forename: V S
authors.initials: VS
authors.lastname: Behar
authors.forename: Y
authors.initials: Y
authors.lastname: Kong
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000800:Angioplasty, Balloon; D001026:Coronary Artery Bypass; D004630:Emergencies; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000401:mortality* / Q000503:physiopathology / Q000628:therapy; D012770:Shock, Cardiogenic / Q000401:mortality; D013318:Stroke Volume; D014654:Vascular Patency
chemical_list: D005343:Fibrinolytic Agents